Metformin targets c-MYC oncogene to prevent prostate cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Carcinogenesis

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/carcin/bgt307PMID 24130167PMCID PMC3845895
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplitude modulation of androgen signaling by c-MYC.

  2013cited by this paper
• Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer

  2012cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

  2012cited by this paper
• A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

  2012cited by this paper
• Metformin, an Antidiabetic Agent Reduces Growth of Cutaneous Squamous Cell Carcinoma by Targeting mTOR Signaling Pathway †

  2012cited by this paper
• Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.

  2012cited by this paper
• Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation

  2012cited by this paper
• Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC

  2012cited by this paper
• Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

  2011cited by this paper
• Metformin Induces G1 Cell Cycle Arrest and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma Cells

  2011cited by this paper
• MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors

  2011cited by this paper
• New hormonal therapies for castration-resistant prostate cancer.

  2011cited by this paper
• Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.

  2011cited by this paper
• Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes

  2010cited by this paper
• The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.

  2010cited by this paper
• Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling

  2010cited by this paper
• MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells

  2010cited by this paper
• Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

  2010cited by this paper
• Inhibitory Effects of Megakaryocytic Cells in Prostate Cancer Skeletal Metastasis

  2010cited by this paper
• The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• MYC and Prostate Cancer.

  2010cited by this paper
• The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

  2009cited by this paper
• The Axin1 scaffold protein promotes formation of a degradation complex for c‐Myc

  2009cited by this paper
• MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

  2009cited by this paper
• The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

  2008cited by this paper
• Hormone-refractory and metastatic prostate cancer - palliative radiotherapy.

  2008cited by this paper
• Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

  2008cited by this paper
• Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion

  2006cited by this paper
• Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.

  2006cited by this paper
• Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

  2005cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

  2004cited by this paper
• The LKB1 tumor suppressor negatively regulates mTOR signaling.

  2004cited by this paper
• Review of allelic loss and gain in prostate cancer

  2004cited by this paper
• Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

  2003cited by this paper
• Will mTOR inhibitors make it as cancer drugs?

  2003cited by this paper
• Transforming growth factor-beta 1 induces apoptosis through down-regulation of c-myc gene and overexpression of p27Kip1 protein in cervical carcinoma.

  1998cited by this paper
• Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation.

  1998cited by this paper
• Transforming Growth Factor-β1 Induces Apoptosis through Down-Regulation of c-mycGene and Overexpression of p27Kip1Protein in Cervical Carcinoma

  1998cited by this paper
• Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

  1997cited by this paper
• Apoptosis induced by c-myc overexpression is dependent on growth conditions.

  1995cited by this paper
• Prostatic intraepithelial neoplasia: a potential precursor lesion of prostatic adenocarcinoma.

  1995cited by this paper
• Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

  1994cited by this paper
• Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells

  1994cited by this paper
• Mapping of the MYC gene to band 8q24.12----q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization.

  1991cited by this paper
• Premalignant lesions of the prostate.

  1988cited by this paper
• Molecular analysis of the c-myc locus in normal tissue and in avian leukosis virus-induced lymphomas

  1982cited by this paper
• The LNCaP cell line--a new model for studies on human prostatic carcinoma.

  1980cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper

• Influence of diabetes mellitus and anti-diabetic drugs on pathophysiology and prognosis for primary prostate cancer.

  2026cites this paper
• Diabetes Mellitus and the Prostate: The Odd Pairing

  2025cites this paper
• TCP1 promotes the progression of malignant tumours by stabilizing c-Myc through the AKT/GSK-3β and ERK signalling pathways

  2025cites this paper
• Salicylate-Elicited Activation of AMP-Activated Protein Kinase Directly Triggers Degradation of C-Myc in Colorectal Cancer Cells

  2025cites this paper
• Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers.

  2024cites this paper
• Identification of glucose-independent and reversible metabolic pathways associated with anti-proliferative effect of metformin in liver cancer cells

  2024cites this paper
• Reversible downregulation of MYC in a spheroid model of metastatic epithelial ovarian cancer

  2024cites this paper
• Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against TMPRSS2-ERG (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer

  2023cites this paper
• Metformin use and hospital attendance‐related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based cohort study

  2023cites this paper
• Obesity under the moonlight of c-MYC

  2023cites this paper
• Risk analysis of metformin use in prostate cancer: a national population-based study

  2023cites this paper
• Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation.

  2022cites this paper
• New Potentiometric Sensor for Determination of Metformin

  2022cites this paper
• Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models

  2022cites this paper
• Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study

  2022cites this paper
• Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells

  2022cites this paper
• Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers

  2022cites this paper
• GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia

  2022cites this paper
• Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells

  2022cites this paper
• Regulation and role of CAMKK2 in prostate cancer

  2022cites this paper
• Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients

  2022cites this paper
• Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models

  2022influential citation
• Potent Synergistic Effect on C-Myc–Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor

  2021cites this paper
• The Effect of Metformin on Expression of Long Non-coding RNA H19 in Endometrial Cancer

  2021cites this paper
• The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

  2021cites this paper
• Hybrid Materials Based on Dimethylbiguanide (Metformin) and Copolymer of N-Vinylpyrrolidone with Triethylene Glycol Dimethacrylate

  2021cites this paper
• Undercover Toxic Ménage à Trois of Amylin, Copper (II) and Metformin in Human Embryonic Kidney Cells

  2021cites this paper
• Metformin Inhibits Esophageal Squamous Cell Carcinoma Viability and Mobility in vitro through Down-regulation of Long Non-coding RNA CCAT1 and SPRY4-IT1

  2021cites this paper
• Distinct roles for the RNA-binding protein Staufen1 in prostate cancer

  2021cites this paper
• Protective Effects of Metformin against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer.

  2021cites this paper
• GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy

  2021cites this paper
• Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models

  2021cites this paper
• Metformin Decreases 2-HG Production through the MYC-PHGDH Pathway in Suppressing Breast Cancer Cell Proliferation

  2021cites this paper
• A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

  2021cites this paper
• Metformin suppressed tumor necrosis factor-α-induced epithelial-mesenchymal transition in prostate cancer by inactivating the NF-κB signaling pathway

  2020cites this paper
• The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.

  2020cites this paper
• Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer

  2020cites this paper
• Association between metformin medication, genetic variation and prostate cancer risk

  2020cites this paper
• If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic

  2020cites this paper
• miR-193b exhibits mutual interaction with MYC, and suppresses growth and metastasis of osteosarcoma

  2020cites this paper
• Association between metformin medication, genetic variation and prostate cancer risk

  2020cites this paper
• Clinical, cellular and molecular evidence of the additive antitumor effects of biguanides and statins in prostate cancer.

  2020cites this paper
• Impact of Putative Chemo-preventative Agents on Prostate Cancer Diagnosis among Men with a Negative First Prostate Biopsy

  2020cites this paper
• Identification of Differentially Methylated Regions Associated with a Knockout of SUV39H1 in Prostate Cancer Cells

  2020cites this paper
• Effects of metformin and phenformin on apoptosis and epithelial‐mesenchymal transition in chemoresistant rectal cancer

  2019cites this paper
• Metformin alters signaling induced crosstalk and homeostasis in the carcinogenesis paradigm “Epistemology of the origin of cancer”

  2019cites this paper
• Metformin delays AKT/c‐Met‐driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation

  2019cites this paper
• Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.

  2019cites this paper
• Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.

  2019cites this paper
• Targeting cellular metabolism to reduce head and neck cancer growth

  2019cites this paper
• Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database

  2019cites this paper
• Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study

  2019cites this paper
• Inhibition of Karyopherin beta 1 suppresses prostate cancer growth

  2019cites this paper
• Metformin use and prostate cancer risk

  2019cites this paper
• D-galactose induces astrocytic aging and contributes to astrocytoma progression and chemoresistance via cellular senescence

  2019cites this paper
• New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of rapamycin pathways

  2018cites this paper
• Unique Features of Metformin: A Combined Experimental, Theoretical, and Simulation Study of Its Structure, Dynamics, and Interaction Energetics with DNA Grooves.

  2018cites this paper
• The Effect of Metformin upon Spermatogenesis in Mice

  2018cites this paper
• SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.

  2018cites this paper
• Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression

  2018cites this paper
• Chronic exposure to microcystin-leucine-arginine promoted proliferation of prostate epithelial cells resulting in benign prostatic hyperplasia.

  2018cites this paper
• Metformin blocks MYC protein synthesis in colorectal cancer via mTOR‐4EBP‐eIF4E and MNK1‐eIF4G‐eIF4E signaling

  2018cites this paper
• Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts.

  2018cites this paper
• Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.

  2018cites this paper
• Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells

  2018cites this paper
• Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy.

  2018cites this paper
• Inhibition of bioenergetic metabolism by the combination of metformin and 2-deoxyglucose highly decreases viability of feline mammary carcinoma cells.

  2017cites this paper
• Metformin: A Bridge between Diabetes and Prostate Cancer

  2017cites this paper
• Targeting MYC Dependence by Metabolic Inhibitors in Cancer

  2017cites this paper
• Effect of NPM1 type B mutation on the proliferation, invasion and chemosensitivity of THP-1 leukemia cells.

  2017cites this paper
• A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.

  2017cites this paper
• Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway

  2017cites this paper
• A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer

  2017cites this paper
• MYC and AMPK–Save Energy or Die!

  2017cites this paper
• Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy

  2017cites this paper
• Expression of Wnt3a in hepatocellular carcinoma and its effects on cell cycle and metastasis

  2017cites this paper
• Role of metformin in inhibiting estrogen-induced proliferation and regulating ERα and ERβ expression in human endometrial cancer cells.

  2017cites this paper
• Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives

  2017cites this paper
• PSCA promotes prostate cancer proliferation and cell‐cycle progression by up‐regulating c‐Myc

  2017cites this paper
• UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis

  2017cites this paper
• Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression

  2017cites this paper
• Metformin inhibits SUV39H1-mediated migration of prostate cancer cells

  2017cites this paper
• Metformin: from mechanisms of action to advanced clinical use

  2017cites this paper
• Molecular targets of metformin antitumor action

  2016cites this paper
• Anti-tumor activity of metformin: from metabolic and epigenetic perspectives

  2016cites this paper
• Potential role for metformin in urologic oncology

  2016cites this paper
• Benefits of Metformin Use for Cholangiocarcinoma.

  2016cites this paper
• Repurposing old drugs to chemoprevention: the case of metformin.

  2016cites this paper
• Repurposing Drugs for Cancer Prevention.

  2016cites this paper
• Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.

  2016cites this paper
• The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.

  2016cites this paper
• Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells

  2016cites this paper
• Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma.

  2016cites this paper
• Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine.

  2016cites this paper
• Autophagy and protein kinase RNA‐like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin‐induced apoptosis

  2016cites this paper
• SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway

  2015cites this paper
• Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice

  2015cites this paper
• Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells

  2015cites this paper
• When is a Proteinase Inhibitor a Hormone? The Strange Tale of α2-Macroglobulin

  2015cites this paper
• Mouse Models to Study Metformin Effects in Carcinogenesis

  2015cites this paper